List view / Grid view
The European Medicines Agency (EMA) announced it will provide free advice to those working on COVID-19 therapeutics and vaccines in the hopes of accelerating approval of a treatment.
According to a report, supply disruption scares and price hikes due to COVID-19 are a 'wake-up call' for India to reduce its dependence on China for APIs.
An EU Executive Steering Group will discuss how to address the impact of medicine shortages caused due to COVID-19, says the EMA.
The UK government has pledged funding of £22 billion per year into R&D by 2025 in its Budget, just days after a further £46 million was invested into coronavirus research.
The US agencies have issued letters to seven companies, and removed online listings from others, whose products falsely claim to prevent or treat coronavirus.
An anti-SARS-CoV-2 polyclonal hyperimmune globulin (H-IG) is being developed to treat infected, high-risk individuals with COVID-19.
The US NIH has initiated a clinical trial for remdesivir and two pharmaceutical companies will work together to manufacture antibody treatments to tackle the coronavirus.
The government in the UK has told pharmaceutical businesses to examine the risk that coronavirus poses to the supply chain and retain any stockpiles from Brexit to mitigate shortages.
The EMA has released a statement on its efforts to support the development of a treatment for the novel coronavirus (2019-nCoV).
The UK Health Secretary announced the government will give Coalition for Epidemic Preparedness Innovations (CEPI) £20 million to research vaccines for the 2019 novel coronavirus (2019-nCoV).
Johnson & Johnson announced Janssen Pharmaceutical Companies will work collaboratively to screen for antiviral therapies and vaccine therapies against 2019-nCoV.
The US FDA has revealed its action plan to aid in the development and advancement of diagnostics and medical countermeasures to combat the novel coronavirus 2019.
The CEPI has announced three respective projects with Inovio, the University of Queensland and Moderna, to develop a vaccine for the novel coronavirus, nCoV-2019.
